Further support for the use of a RARγ antagonist to treat PCa is that a RARγ network governs androgen signaling within and disease progression of PCa, as several of the target genes (e.g., SOX15) are associated with worse disease-free survival (Long et al., 2019). This evidence concerns the gene RARG and posterior cortical atrophy.